Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc (ACAD) Wheel Strategy
ACAD wheel strategy scan found 11 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 947.6%.
Read more
Running a ACAD wheel strategy lets you generate consistent premium income on Acadia Pharmaceuticals Inc while setting your own entry and exit prices on the underlying. Acadia Pharmaceuticals Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own ACAD, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best ACAD wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on ACAD, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable ACAD wheel from a losing one.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the ACAD wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your ACAD wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Sep 18, 2026 | 26.00 | $0.10 | $1.35 | -0.35 | 2 | 99% | 76.8% | 947.6% | 1,413 |
| Oct 16, 2026 | 26.00 | $0.70 | $2.80 | -0.36 | 30 | 99% | 51.6% | 131.0% | 11 |
| Oct 16, 2026 | 25.00 | $0.45 | $2.48 | -0.32 | 30 | 99% | 56.6% | 120.5% | 2 |
| Oct 16, 2026 | 24.00 | $0.75 | $2.33 | -0.29 | 30 | 99% | 61.6% | 117.9% | 22 |
| Oct 16, 2026 | 23.00 | $0.45 | $2.08 | -0.25 | 30 | 99% | 66.7% | 109.8% | 95 |
| Nov 20, 2026 | 24.00 | $0.40 | $2.55 | -0.29 | 65 | 99% | 53.4% | 59.7% | 0 |
| Oct 16, 2026 | 21.00 | $0.05 | $0.95 | -0.16 | 30 | 99% | 76.6% | 55.0% | 4 |
| Nov 20, 2026 | 23.00 | $0.15 | $2.18 | -0.25 | 65 | 99% | 57.0% | 53.1% | 0 |
| Jan 15, 2027 | 22.00 | $1.50 | $2.75 | -0.24 | 121 | 99% | 52.6% | 37.7% | 163 |
| Dec 18, 2026 | 23.00 | $0.05 | $2.03 | -0.25 | 93 | 99% | 52.8% | 34.6% | 1 |
As of September 17, 2026
Run the Wheel on ACAD With Confidence
Find the best ACAD wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→